Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KabiVitrum's Antithrombin III

Executive Summary

Pasteurized human antithrombin III orphan treatment, ATnativ, introduced Feb. 5. Product is for the treatment of the estimated 3,000 U.S. patients with antithrombin III deficiency. ATnativ was approved Dec. 13. By the end of February, KabiVitrum will detail product to hematologists and hospital pharmacists by mail; telemarketing is also planned. Company will detail product in conjunction with its antithrombin III diagnostic Coatest. ATnativ's wholesale price is $295/500 I.U. bottle.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel